Investigational Drug Information for Obicetrapib
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $100
Remove trial restrictions
What is the drug development status for Obicetrapib?
Obicetrapib is an investigational drug.
There have been 8 clinical trials for Obicetrapib. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Atherosclerosis. The leading clinical trial sponsors are NewAmsterdam Pharma and [disabled in preview].
There are three US patents protecting this investigational drug and eighty-nine international patents.
Summary for Obicetrapib
|US Patent Applications||24|
|WIPO Patent Applications||20|
|Japanese Patent Applications||2|
|Clinical Trial Progress||Phase 2 (2022-02-01)|
Recent Clinical Trials for Obicetrapib
|Randomized Study in Patients With HeFH to Evaluate Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies||NewAmsterdam Pharma||Phase 3|
|A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.||NewAmsterdam Pharma||Phase 2|
|Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy||NewAmsterdam Pharma||Phase 2|
Clinical Trial Summary for Obicetrapib
Top disease conditions for Obicetrapib
Top clinical trial sponsors for Obicetrapib
US Patents for Obicetrapib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Obicetrapib||⤷ Sign Up||Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives||DEZIMA PHARMA B.V. (Naarden, NL)||⤷ Sign Up|
|Obicetrapib||⤷ Sign Up||Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors||DEZIMA PHARMA B.V. (NL)||⤷ Sign Up|
|Obicetrapib||⤷ Sign Up||Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases||DEZIMA PHARMA BV (NL)||⤷ Sign Up|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
International Patents for Obicetrapib
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Obicetrapib||Argentina||AR101509||2034-08-12||⤷ Sign Up|
|Obicetrapib||Australia||AU2015302407||2034-08-12||⤷ Sign Up|
|Obicetrapib||Brazil||BR112017002873||2034-08-12||⤷ Sign Up|
|Obicetrapib||Canada||CA2958040||2034-08-12||⤷ Sign Up|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|